{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:08:52Z","timestamp":1773014932834,"version":"3.50.1"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This real\u2010world study evaluated the effectiveness and safety of switching basal insulin (BI) to insulin glargine 300\u2009U\/mL (Gla\u2010300) in adults with inadequately controlled type 2 diabetes mellitus (T2DM), previously receiving basal\u2010supported oral therapy plus prandial insulin (BOTplus) or multiple (\u22653) daily injections (MDI) of short\u2010acting insulins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      This non\u2010interventional, multicentre, open\u2010label, prospective 12\u2010month study in Germany included adult participants (\u226518\u2009years) with T2DM, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      between 7.5% and 10.0%, and fasting plasma glucose (FPG) &gt;130\u2009mg\/dL (&gt;7.2\u2009mmol\/L). The participants were switched from non\u2010Gla\u2010300 BOTplus or MDI regimen (including Gla\u2010100, IDet, IDeg, or NPH) to Gla\u2010300. The primary endpoint was the duration of glycaemic target achievement, defined as the time between \u22652 FPG values \u2264110\u2009mg\/dL (\u22646.1\u2009mmol\/L) or \u22651HbA\n                      <jats:sub>1c<\/jats:sub>\n                      value below the predefined target.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 1217 participants, 582 completed the documentation of the 12\u2010month Gla\u2010300 treatment (FAS2\u2010M12). Target achievement with Gla\u2010300 was reported for 280\/582 FAS2\u2010M12 participants (48.1%). The median response duration was 295\u2009days (95% CI: 226, 381). The mean (\u00b1SD) change in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and FPG from baseline was \u22120.56% (\u00b11.08;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009568) and \u221229.3 mg\/dL or 1.63\u2009mmol\/L (\u00b154.95;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009540) at month 12, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Numbers and incidence of hypoglycaemia were similar before starting Gla\u2010300 therapy and at month 12. Body weight (100.1\u2009kg\u2009\u00b1\u200921.07;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009571 at baseline) remained unchanged until month 12 (mean change: \u22120.0\u2009kg\u2009\u00b1\u20098.40;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009513).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching BI to Gla\u2010300 from a BOTplus or MDI regimen with prior insulin Gla\u2010100, IDeg, IDet, or NPH improved glycaemic control in participants with inadequately controlled T2DM over 12\u2009months without increasing hypoglycaemia risk or weight gain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70417","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:22:17Z","timestamp":1768897337000},"page":"2237-2244","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of switching basal insulin to insulin glargine 300 U\/\n                    <scp>mL<\/scp>\n                    in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo\u2010Neo\n                    <scp>T2DM<\/scp>\n                    study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3400-5790","authenticated-orcid":false,"given":"Stefan","family":"Pscherer","sequence":"first","affiliation":[{"name":"Clinic of Internal Medicine III, Diabetology and Nephrology Sophien\u2010 und Hufeland\u2010Klinikum gGmbH  Weimar Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4987-1961","authenticated-orcid":false,"given":"Andreas","family":"Fritsche","sequence":"additional","affiliation":[{"name":"Hospital for Internal Medicine IV University of Tuebingen  Tuebingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Anderten","sequence":"additional","affiliation":[{"name":"Joint Practice Anderten, Krok &amp; Partner  Hildesheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9002-5305","authenticated-orcid":false,"given":"Katrin","family":"Pegelow","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Deutschland GmbH  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Y.","family":"Han","sequence":"additional","affiliation":[{"name":"Sanofi\u2010Aventis Deutschland GmbH  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6853-0302","authenticated-orcid":false,"given":"Martin","family":"Pfohl","sequence":"additional","affiliation":[{"name":"Medical Hospital I, Ev. Bethesda Hospital  Duisburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-7310","authenticated-orcid":false,"given":"Jochen","family":"Seufert","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center Faculty of Medicine, University of Freiburg  Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"International Diabetes Federation.IDF Diabetes Altas 2021. 10th edition. Accessed July 29 2024.https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf"},{"issue":"1","key":"e_1_2_10_3_1","first-page":"S19","article-title":"Standards of care in diabetes \u2013 2023","volume":"46","author":"American Diabetes Association","year":"2022","journal-title":"Diabetes Care"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13818"},{"key":"e_1_2_10_9_1","unstructured":"Bundes\u00e4rztekammer (B\u00c4K) Kassen\u00e4rztliche Bundesvereinigung (KBV) Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF).Nationale VersorgungsLeitlinie Typ\u20102\u2010Diabetes \u2013 Teilpublikation der Langfassung 2. Auflage. Version 1.2021."},{"issue":"02","key":"e_1_2_10_10_1","first-page":"S159","article-title":"Therapie des typ\u20102\u2010diabetes","volume":"17","author":"Landgraf R","year":"2022","journal-title":"Diabetologie und Stoffwechsel"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13952"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14549"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14405"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800256"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0168"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000409"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejsp.401"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/full-xml\/10.1111\/dom.70417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.70417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:01:01Z","timestamp":1773010861000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.70417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/dom.70417"],"URL":"https:\/\/doi.org\/10.1111\/dom.70417","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70417\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70417\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70417\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70417\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70417\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70417\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70417\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}